The DNAJC19 Knockout Huh-7 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population derived from the Huh-7 human hepatocellular carcinoma line, with targeted disruption of the DNAJC19 gene. This polyclonal knockout model provides a heterogeneous loss-of-function tool for dissecting DNAJC19??s contributions to mitochondrial protein import, cardiolipin remodeling, and cristae architecture, without the need for single-cell cloning.
The Huh-7 cell line, originally isolated from a liver tumor, displays epithelial morphology and retains many hepatocyte-specific functions including lipoprotein secretion and permissiveness to hepatitis C virus. Its robust mitochondrial network and metabolic activity make it an ideal host for studying mitochondrial dynamics and import processes, providing a physiologically relevant hepatic cancer context for DNAJC19 functional analysis.
DNAJC19 is a DnaJ-domain co-chaperone that localizes to the mitochondrial inner membrane and associates with the TIM23 translocase complex, directly binding TIM23, TIM17, and TIM50. It also interacts with Prohibitin to modulate cardiolipin metabolism and cristae morphology. Upstream, DNAJC19 expression is driven by PGC-1?? and NRF1, while downstream its loss impairs TIM23-mediated protein import, decreases mitochondrial membrane potential, and reduces ATP output. DNAJC19 functionally converges with mitochondrial dynamics factors OPA1, MFN1, and MFN2, linking import machinery to cristae remodeling.
In Huh-7 hepatocellular carcinoma cells, DNAJC19 knockout models hepatic mitochondrial dysfunction, allowing exploration of how defects in protein import and cardiolipin remodeling impact cancer cell metabolism, stress adaptation, and viability. Given the liver??s high mitochondrial content, this model is pertinent for investigating mitochondrial pathologies underlying DCMA and related disorders. It enables the study of DNAJC19’s role in maintaining cristae integrity and respiratory capacity within a transformed hepatocyte environment.
Researchers can employ Western blotting for TIM23 components, TOM20 immunofluorescence for morphology, JC-1 staining for membrane potential, ATP luminescent assays, and Seahorse respirometry to evaluate mitochondrial function. The polyclonal nature of the knockout population minimizes clonal bias, enhancing its use in high-content drug screening for mitochondrial dysfunction. This product is suitable for mechanistic studies, disease modeling, and therapeutic target validation. For inquiries, contact Ascent Research.
